Biocept appoints new senior vice president, chief commercial officer
11 September 2018 -

It was reported on Monday that Biocept Inc (NASDAQ: BIOC), a commercial provider of liquid biopsy cancer tests, has named Edwin C. Hendrick as its new senior vice president and chief commercial officer.

Hendrick has more than 25 years of sales and commercial leadership experience in the healthcare industry. Prior to GenomeDx, he was executive vice president, Sales and Marketing of PLUS Diagnostics, and served as an executive with US Labs. He began his career in sales for Abbott Laboratories.

Michael Nall, president and chief executive officer of Biocept, was cited as saying: "Edwin's outstanding experience developing successful commercial organizations in early-stage companies is a natural fit for Biocept, as we aim to continue to build our market presence in the emerging liquid biopsy segment. His proven ability to work across entire organizations to improve functional areas such as strategic marketing, sales, billing, health plan access, and customer service will provide needed depth to our management bench as Biocept grows. All of us at Biocept extend a warm welcome to Edwin."